Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has been granted marketing authorization from the European Commission for Tandemact, a combination tablet for diabetes patients to rival the standard multiple medications for the illness.
Subscribe to our email newsletter
Tandemact is a combination of Actos and glimepiride HCl for type 2 diabetes. Takeda believes combining these medications may provide patients with an easier way for diabetes patients to take the two drugs.
Actos is a member of the thiazolidinedione class of “insulin-sensitizing” agents and it directly targets insulin resistance. Glimepiride acts primarily by increasing the amount of insulin produced by the pancreas. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.
“We are very pleased with this approval of Tandemact, which enables us to provide an additional treatment option for the patients with type 2 diabetes,” said Dr Masaomi Miyamoto, general manager of Pharmaceutical Development Division of Takeda.